Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

NCT03978000 is registered in ClinicalTrials.gov with Infant Bacterial Therapeutics as lead sponsor.

NCT NCT03978000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03978000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study
Lead sponsor
Infant Bacterial Therapeutics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 4, 2019
Completion date
July 31, 2024
Enrollment
2,158 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

necrotizing enterocolitis